An engineered factor Va prevents bleeding induced by anticoagulant wt activated protein C.

An increased risk of bleeding is observed in patients receiving activated protein C (APC), which may be a limiting factor for the application of novel APC therapies. Since APC's therapeutic effects often require its cytoprotective activities on cells but not APC's anticoagulant activities,...

Full description

Bibliographic Details
Main Authors: Annette von Drygalski, Vikas Bhat, Andrew J Gale, Laurent Burnier, Thomas J Cramer, John H Griffin, Laurent O Mosnier
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC4134195?pdf=render